Denali Therapeutics (Denali Therapeutics) Total Liabilities

: $123.0 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

Denali Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $123.0 Mil.

Denali Therapeutics's quarterly Total Liabilities declined from Jun. 2023 ($118.91 Mil) to Sep. 2023 ($118.45 Mil) but then increased from Sep. 2023 ($118.45 Mil) to Dec. 2023 ($122.96 Mil).

Denali Therapeutics's annual Total Liabilities declined from Dec. 2021 ($441.87 Mil) to Dec. 2022 ($417.81 Mil) and declined from Dec. 2022 ($417.81 Mil) to Dec. 2023 ($122.96 Mil).

Denali Therapeutics Total Liabilities Historical Data

The historical data trend for Denali Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

158.34

453.75

441.87

417.81

122.96

Denali Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities																417.81	442.64	118.91	118.45	122.96

Denali Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Denali Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	77.982	+	(44.981	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	123.0

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1153.917	-	1030.954
	=	123.0

Denali Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	77.982	+	(44.981	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	123.0

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	1153.917	-	1030.954
	=	123.0

Denali Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Denali Therapeutics (Denali Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (NAS:DNLI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

4DN:Germany

Address

161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.denalitherapeutics.com

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Executives

Vicki L Sato	director	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Carole Ho	officer: Chief Medical Officer	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Ryan J. Watts	director, officer: President and CEO	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Steve E. Krognes	officer: CFO and Treasurer	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Alexander O. Schuth	officer: COO and Secretary	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Marc Tessier-lavigne	director	1 DNA WAY, SOUTH SAN FRANCISCO CA 94080
Erik Harris	director	60 LEVERONI COURT, NOVATO CA 94949
Douglas K Bratton	10 percent owner	201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102
Nancy Thornberry	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
David P Schenkein	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Arch Venture Partners Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Viii, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631